Stay updated with breaking news from Poster Section. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Initial data from the Phase 1 dose escalation part of the OBT076 trial in adult patients with advanced solid tumors indicated that OBT076 had a favorable...
/PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...
/PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for...